Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pyridazinone compounds, their preparation methods, pharmaceutical compositions and uses thereof

The technology of a compound, pyridazinone, applied in the field of medicinal chemistry, can solve the problems of large difference in activity level at the cell level and poor physical and chemical properties

Active Publication Date: 2018-02-27
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the poor physical and chemical properties of amide and carbamate groups, the activity of this type of compound at the cell level is quite different from that at the enzyme level.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyridazinone compounds, their preparation methods, pharmaceutical compositions and uses thereof
  • Pyridazinone compounds, their preparation methods, pharmaceutical compositions and uses thereof
  • Pyridazinone compounds, their preparation methods, pharmaceutical compositions and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0124] Preparation Example 1: Preparation of Intermediate I-1:

[0125]

[0126] Put 40ml of DMF in a round bottom flask, slowly add 6.89ml of POCl under ice-cooling 3 (Phosphorus oxychloride), after the dropwise addition, after stirring in an ice bath for 35min, slowly add a DMF solution of 5g of 6-fluoroindole in a constant pressure dropping funnel, and stir for 40min at 35°C. The reaction solution gradually changed from colorless to red. After TLC showed that the reaction was complete, 100 ml of 19.3 mmol / L NaOH aqueous solution was added, and vigorously stirred at 80° C. for 30 min. The reaction solution was cooled, and ethyl acetate was added for extraction, 30 ml each time, for a total of three extractions. The organic layers were combined, dried over anhydrous sodium sulfate, evaporated to dryness, and subjected to silica gel column chromatography to obtain 4.5 g of intermediate I-1 (white solid, yield 75%).

[0127] 1 H NMR (300MHz,D 2 O)δ10.01(s,1H),8.24(dd,J=...

preparation Embodiment 2

[0128] Preparation Example 2: Preparation of Intermediate I-2:

[0129]

[0130]Dissolve 1.5g of 3-formyl-6-fluoroindole (ie intermediate I-1) in isopropanol, add 150mg of palladium carbon and 3.2g of sodium borohydride, and reflux overnight at 80°C. After TLC showed that the substrate disappeared, the palladium carbon was removed by filtration. After the filtrate was concentrated, the excess sodium borohydride was quenched by adding water, and extracted with ethyl acetate, 15 ml each time, three times. The organic layers were combined, dried over anhydrous sodium sulfate, evaporated to dryness, and silica gel column chromatography to obtain intermediate I-2 (white solid, quantitative yield).

[0131] 1 H NMR (300MHz, CDCl 3 )δ7.60(s,1H),7.56(dd,J=7.5,5.1Hz,1H),7.03(dd,J=8.0,1.4Hz,1H),6.98–6.90(m,2H),2.34(s ,3H).

preparation Embodiment 3

[0132] Preparation Example 3: Preparation of Intermediate I-3:

[0133]

[0134] 1 g of 3-methyl-6-fluoroindole (ie intermediate I-2) and 1 g of dichloropyridazine were dissolved in reevaporated and dried THF under nitrogen protection. Add 270 mg NaH under ice cooling and stir rapidly. After the reaction was stable, the ice bath was removed and stirred at room temperature. After the complete conversion of the substrate was detected by TLC, excess water was added to quench the unreacted NaH, and extracted with ethyl acetate, 20 ml each time, twice. The combined organic layers were dried and concentrated. The crude product was dissolved in glacial acetic acid and refluxed at 120 °C overnight. After stopping the reaction, the glacial acetic acid was distilled off under reduced pressure, and the crude product was dissolved in 100ml of ethyl acetate, washed 5 times with 50ml of water each time. The organic layer was dried, concentrated, and subjected to silica gel column chr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is in the scope of the field of pharmaceutical chemistry. Specifically, the present invention relates to pyridazinone compounds of formula (I) or isomers, pharmaceutically acceptable salts, esters, prodrugs or solvates thereof, preparation method, pharmaceutical compositions thereof and use in manufacture of tyrosine kinase inhibitors, specially c-Met inhibitors. Said compounds or pharmaceutical compositions are used to prevent and / or treat tumor diseases related to c-Met abnormality as tyrosine kinase inhibitors, specially c-Met inhibitors.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry. Specifically, the present invention relates to a new class of pyridazinone compounds or their isomers or pharmaceutically acceptable salts, esters, prodrugs or solvates, their preparation methods, pharmaceutical compositions and their use in the preparation of phenolic compounds. Use in amino acid kinase inhibitors, especially c-Met inhibitors. The compound or its pharmaceutical composition can be used as a tyrosine kinase inhibitor, especially as a c-Met inhibitor, to prevent and / or treat tumor diseases related to c-Met abnormality. Background technique [0002] Malignant tumors seriously threaten human survival and health, and the prevention and / or treatment of malignant tumors is a worldwide problem. At present, a large number of anti-tumor targets have been discovered, among which protein tyrosine kinases have become a class of anti-tumor targets with good prospects. [0003] The recepto...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D401/14C07D471/04A61K31/5377A61K31/501A61P11/00A61P35/02A61P35/00A61P27/02A61P37/06A61P27/06A61P1/04A61P15/00A61P7/10
CPCC07D401/14C07D471/04A61K31/50A61K31/501A61K31/5377A61P1/04A61P7/10A61P11/00A61P15/00A61P27/02A61P27/06A61P35/00A61P35/02A61P37/06
Inventor 胡有洪耿美玉邢唯强丁健艾菁
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com